UBS: Lowered target price of Kangji Medical (06185) to 52.4 Hong Kong dollars. First quarter performance in line with expectations.

Wisdom Financial APP learned that UBS released a research report stating that CanSino Biologics (06185) performed in line with expectations in the first quarter of this year. During the period, revenue was 190 million yuan, a year-on-year increase of 38.7%, slightly higher than the bank's forecasted 34% growth for the full year of 2026; net loss was 40 million yuan, compared to the bank's forecast of a full-year profit of 337 million yuan this year. UBS adjusted its earnings per share forecast for the group for the years 2026 to 2028, lowering them from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan respectively. The target price was lowered from 59.8 Hong Kong dollars to 52.4 Hong Kong dollars; with a rating of "buy".